Molecular Diagnosis and Therapy of Kidney Cancer

Overview

Journal Annu Rev Med

Publisher Annual Reviews

Specialty General Medicine

Date 2010 Jan 12

PMID 20059341

Citations 77

Authors

W Marston Linehan

Gennady Bratslavsky

Peter A Pinto

Laura S Schmidt

Len Neckers

Donald P Bottaro

Ramaprasad Srinivasan

Affiliations

Soon will be listed here.

Abstract

Kidney cancer is not a single disease; it is made up of a number of cancers that occur in the kidney, each having a different histology, following a different clinical course, responding differently to therapy, and caused by a different gene. Study of the genes underlying kidney cancer has revealed that it is fundamentally a metabolic disorder. Understanding the genetic basis of cancer of the kidney has significant implications for diagnosis and management of this disease. VHL is the gene for clear cell kidney cancer. The VHL protein forms a complex that targets the hypoxia-inducible factors for ubiquitin-mediated degradation. Knowledge of this pathway provided the foundation for the development of novel therapeutic approaches now approved for treatment of this disease. MET is the gene for the hereditary form of type 1 papillary renal carcinoma and is mutated in a subset of sporadic type 1 papillary kidney cancers. Clinical trials are currently ongoing with agents targeting the tyrosine kinase domain of MET in sporadic and hereditary forms of papillary kidney cancer. BHD is the gene for the hereditary type of chromophobe kidney cancer. It is thought to be involved in energy and/or nutrient sensing through the AMPK and mTOR signaling pathways. Hereditary leiomyomatosis renal cell carcinoma, a hereditary form of type 2 papillary renal carcinoma, is caused by inactivation of a Krebs cycle enzyme due to mutation. Knowledge of these kidney cancer gene pathways has enabled new approaches in the management of this disease and has provided the foundation for the development of targeted therapeutics.

Citing Articles

Yang Z, Zhang X, Zhan N, Lin L, Zhang J, Peng L Cancer Med. 2024; 13(11):e7308.

PMID: 38808948 PMC: 11135019. DOI: 10.1002/cam4.7308.

The application of peroxidase mimetic nanozymes in cancer diagnosis and therapy.

Hasan-Abad A, Shabankare A, Atapour A, Hamidi G, Zavareh M, Sobhani-Nasab A Front Pharmacol. 2024; 15:1339580.

PMID: 38333005 PMC: 10851941. DOI: 10.3389/fphar.2024.1339580.

Analysis of expression, immunomodulation and prognostic value in renal cancer using multiomic databases.

Ogbodo A, Mustafov D, Arora M, Lambrou G, Braoudaki M, Siddiqui S Heliyon. 2024; 10(2):e24286.

PMID: 38268823 PMC: 10803920. DOI: 10.1016/j.heliyon.2024.e24286.

Smart Nanozymes for Cancer Therapy: The Next Frontier in Oncology.

P N N, Mehla S, Begum A, Chaturvedi H, Ojha R, Hartinger C Adv Healthc Mater. 2023; 12(25):e2300768.

PMID: 37392379 PMC: 11481082. DOI: 10.1002/adhm.202300768.

Preclinical optimization of a diode laser-based clamp-free partial nephrectomy in a large animal model.

Andrade W, Tang F, Mariotti A, Mancini M, Duarte I, Singer E Sci Rep. 2023; 13(1):9237.

PMID: 37286592 PMC: 10247752. DOI: 10.1038/s41598-023-35891-1.

References

Stolle C, Glenn G, Zbar B, Humphrey J, Choyke P, Walther M . Improved detection of germline mutations in the von Hippel-Lindau disease tumor suppressor gene. Hum Mutat. 1998; 12(6):417-23. DOI: 10.1002/(SICI)1098-1004(1998)12:6<417::AID-HUMU8>3.0.CO;2-K. View

Rogers C, Singh A, Blatt A, Linehan W, Pinto P . Robotic partial nephrectomy for complex renal tumors: surgical technique. Eur Urol. 2007; 53(3):514-21. PMC: 2644902. DOI: 10.1016/j.eururo.2007.09.047. View

Patel P, Senico P, Curiel R, Motzer R . Phase I study combining treatment with temsirolimus and sunitinib malate in patients with advanced renal cell carcinoma. Clin Genitourin Cancer. 2009; 7(1):24-7. PMC: 3740755. DOI: 10.3816/CGC.2009.n.004. View

Yang J, Haworth L, Sherry R, Hwu P, Schwartzentruber D, Topalian S . A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. N Engl J Med. 2003; 349(5):427-34. PMC: 2275324. DOI: 10.1056/NEJMoa021491. View

Walther M, Lubensky I, Venzon D, Zbar B, Linehan W . Prevalence of microscopic lesions in grossly normal renal parenchyma from patients with von Hippel-Lindau disease, sporadic renal cell carcinoma and no renal disease: clinical implications. J Urol. 1995; 154(6):2010-4; discussion 2014-5. View

Schmidt L, Junker K, Nakaigawa N, Kinjerski T, Weirich G, Miller M . Novel mutations of the MET proto-oncogene in papillary renal carcinomas. Oncogene. 1999; 18(14):2343-50. DOI: 10.1038/sj.onc.1202547. View

STEBBINS C, Kaelin Jr W, Pavletich N . Structure of the VHL-ElonginC-ElonginB complex: implications for VHL tumor suppressor function. Science. 1999; 284(5413):455-61. DOI: 10.1126/science.284.5413.455. View

Hasumi H, Baba M, Hong S, Hasumi Y, Huang Y, Yao M . Identification and characterization of a novel folliculin-interacting protein FNIP2. Gene. 2008; 415(1-2):60-7. PMC: 2727720. DOI: 10.1016/j.gene.2008.02.022. View

Rogers C, Metwalli A, Blatt A, Bratslavsky G, Menon M, Linehan W . Robotic partial nephrectomy for renal hilar tumors: a multi-institutional analysis. J Urol. 2008; 180(6):2353-6. PMC: 2648867. DOI: 10.1016/j.juro.2008.08.022. View

10.

Schmidt L, Duh F, Chen F, Kishida T, Glenn G, Choyke P . Germline and somatic mutations in the tyrosine kinase domain of the MET proto-oncogene in papillary renal carcinomas. Nat Genet. 1997; 16(1):68-73. DOI: 10.1038/ng0597-68. View

11.

Linehan W . Targeting VEGF receptors in kidney cancer. Lancet Oncol. 2007; 8(11):956-7. DOI: 10.1016/S1470-2045(07)70322-4. View

12.

Haas N, Uzzo R . Adjuvant therapy for renal cell carcinoma. Curr Oncol Rep. 2008; 10(3):245-52. DOI: 10.1007/s11912-008-0037-4. View

13.

Maxwell P, Wiesener M, Chang G, Clifford S, Vaux E, Cockman M . The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis. Nature. 1999; 399(6733):271-5. DOI: 10.1038/20459. View

14.

Grubb 3rd R, Franks M, Toro J, Middelton L, Choyke L, Fowler S . Hereditary leiomyomatosis and renal cell cancer: a syndrome associated with an aggressive form of inherited renal cancer. J Urol. 2007; 177(6):2074-9. DOI: 10.1016/j.juro.2007.01.155. View

15.

Wilhelm S, Adnane L, Newell P, Villanueva A, Llovet J, Lynch M . Preclinical overview of sorafenib, a multikinase inhibitor that targets both Raf and VEGF and PDGF receptor tyrosine kinase signaling. Mol Cancer Ther. 2008; 7(10):3129-40. DOI: 10.1158/1535-7163.MCT-08-0013. View

16.

Baba M, Hong S, Sharma N, Warren M, Nickerson M, Iwamatsu A . Folliculin encoded by the BHD gene interacts with a binding protein, FNIP1, and AMPK, and is involved in AMPK and mTOR signaling. Proc Natl Acad Sci U S A. 2006; 103(42):15552-7. PMC: 1592464. DOI: 10.1073/pnas.0603781103. View

17.

Nickerson M, Warren M, Toro J, Matrosova V, Glenn G, Turner M . Mutations in a novel gene lead to kidney tumors, lung wall defects, and benign tumors of the hair follicle in patients with the Birt-Hogg-Dubé syndrome. Cancer Cell. 2002; 2(2):157-64. DOI: 10.1016/s1535-6108(02)00104-6. View

18.

Pfaffenroth E, Linehan W . Genetic basis for kidney cancer: opportunity for disease-specific approaches to therapy. Expert Opin Biol Ther. 2008; 8(6):779-90. PMC: 2768039. DOI: 10.1517/14712598.8.6.779. View

19.

Toro J, Nickerson M, Wei M, Warren M, Glenn G, Turner M . Mutations in the fumarate hydratase gene cause hereditary leiomyomatosis and renal cell cancer in families in North America. Am J Hum Genet. 2003; 73(1):95-106. PMC: 1180594. DOI: 10.1086/376435. View

20.

Seyam R, Bissada N, Kattan S, Mokhtar A, Aslam M, Fahmy W . Changing trends in presentation, diagnosis and management of renal angiomyolipoma: comparison of sporadic and tuberous sclerosis complex-associated forms. Urology. 2008; 72(5):1077-82. DOI: 10.1016/j.urology.2008.07.049. View